Cargando…

Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines

Intranasal inactivated influenza vaccines can elicit mucosal immune responses that protect against virus infection. For the development of intranasal inactivated influenza vaccines, effective adjuvants inducing minimal adverse reactions are required. Generally, however, lower toxicity adjuvants have...

Descripción completa

Detalles Bibliográficos
Autores principales: Tazaki, Taiyu, Tabata, Koshiro, Ainai, Akira, Ohara, Yuki, Kobayashi, Shintaro, Ninomiya, Takafumi, Orba, Yasuko, Mitomo, Hideyuki, Nakano, Tetsuo, Hasegawa, Hideki, Ijiro, Kuniharu, Sawa, Hirofumi, Suzuki, Tadaki, Niikura, Kenichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080258/
https://www.ncbi.nlm.nih.gov/pubmed/35540526
http://dx.doi.org/10.1039/c8ra01690a
_version_ 1784702743484563456
author Tazaki, Taiyu
Tabata, Koshiro
Ainai, Akira
Ohara, Yuki
Kobayashi, Shintaro
Ninomiya, Takafumi
Orba, Yasuko
Mitomo, Hideyuki
Nakano, Tetsuo
Hasegawa, Hideki
Ijiro, Kuniharu
Sawa, Hirofumi
Suzuki, Tadaki
Niikura, Kenichi
author_facet Tazaki, Taiyu
Tabata, Koshiro
Ainai, Akira
Ohara, Yuki
Kobayashi, Shintaro
Ninomiya, Takafumi
Orba, Yasuko
Mitomo, Hideyuki
Nakano, Tetsuo
Hasegawa, Hideki
Ijiro, Kuniharu
Sawa, Hirofumi
Suzuki, Tadaki
Niikura, Kenichi
author_sort Tazaki, Taiyu
collection PubMed
description Intranasal inactivated influenza vaccines can elicit mucosal immune responses that protect against virus infection. For the development of intranasal inactivated influenza vaccines, effective adjuvants inducing minimal adverse reactions are required. Generally, however, lower toxicity adjuvants have lower adjuvanticity. In this research, we fabricated nanoparticle-based adjuvants to enhance its adjuvanticity. Herein, we focused on low-molecular-weight polyinosinic-polycytidylic acid, referred to as uPIC(40:400), as a weak and less toxic RNA adjuvant. We conjugated uPIC(40:400) with different shaped gold nanoparticles (AuNPs) electrostatically. Conjugation with gold nanorods, but not spherical AuNPs, markedly enhanced the adjuvanticity of uPIC(40:400), leading to the suppression of viral infection in mice. Notably, conjugation with gold nanorods did not increase the inflammatory cytokine production in dendritic cells. These data indicated that gold nanorods can provide a good platform for enhancing the weak adjuvanticity of uPIC(40:400) while maintaining low inflammatory cytokine production toward the development of intranasal inactivated influenza vaccines.
format Online
Article
Text
id pubmed-9080258
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-90802582022-05-09 Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines Tazaki, Taiyu Tabata, Koshiro Ainai, Akira Ohara, Yuki Kobayashi, Shintaro Ninomiya, Takafumi Orba, Yasuko Mitomo, Hideyuki Nakano, Tetsuo Hasegawa, Hideki Ijiro, Kuniharu Sawa, Hirofumi Suzuki, Tadaki Niikura, Kenichi RSC Adv Chemistry Intranasal inactivated influenza vaccines can elicit mucosal immune responses that protect against virus infection. For the development of intranasal inactivated influenza vaccines, effective adjuvants inducing minimal adverse reactions are required. Generally, however, lower toxicity adjuvants have lower adjuvanticity. In this research, we fabricated nanoparticle-based adjuvants to enhance its adjuvanticity. Herein, we focused on low-molecular-weight polyinosinic-polycytidylic acid, referred to as uPIC(40:400), as a weak and less toxic RNA adjuvant. We conjugated uPIC(40:400) with different shaped gold nanoparticles (AuNPs) electrostatically. Conjugation with gold nanorods, but not spherical AuNPs, markedly enhanced the adjuvanticity of uPIC(40:400), leading to the suppression of viral infection in mice. Notably, conjugation with gold nanorods did not increase the inflammatory cytokine production in dendritic cells. These data indicated that gold nanorods can provide a good platform for enhancing the weak adjuvanticity of uPIC(40:400) while maintaining low inflammatory cytokine production toward the development of intranasal inactivated influenza vaccines. The Royal Society of Chemistry 2018-05-04 /pmc/articles/PMC9080258/ /pubmed/35540526 http://dx.doi.org/10.1039/c8ra01690a Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Tazaki, Taiyu
Tabata, Koshiro
Ainai, Akira
Ohara, Yuki
Kobayashi, Shintaro
Ninomiya, Takafumi
Orba, Yasuko
Mitomo, Hideyuki
Nakano, Tetsuo
Hasegawa, Hideki
Ijiro, Kuniharu
Sawa, Hirofumi
Suzuki, Tadaki
Niikura, Kenichi
Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines
title Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines
title_full Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines
title_fullStr Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines
title_full_unstemmed Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines
title_short Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines
title_sort shape-dependent adjuvanticity of nanoparticle-conjugated rna adjuvants for intranasal inactivated influenza vaccines
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9080258/
https://www.ncbi.nlm.nih.gov/pubmed/35540526
http://dx.doi.org/10.1039/c8ra01690a
work_keys_str_mv AT tazakitaiyu shapedependentadjuvanticityofnanoparticleconjugatedrnaadjuvantsforintranasalinactivatedinfluenzavaccines
AT tabatakoshiro shapedependentadjuvanticityofnanoparticleconjugatedrnaadjuvantsforintranasalinactivatedinfluenzavaccines
AT ainaiakira shapedependentadjuvanticityofnanoparticleconjugatedrnaadjuvantsforintranasalinactivatedinfluenzavaccines
AT oharayuki shapedependentadjuvanticityofnanoparticleconjugatedrnaadjuvantsforintranasalinactivatedinfluenzavaccines
AT kobayashishintaro shapedependentadjuvanticityofnanoparticleconjugatedrnaadjuvantsforintranasalinactivatedinfluenzavaccines
AT ninomiyatakafumi shapedependentadjuvanticityofnanoparticleconjugatedrnaadjuvantsforintranasalinactivatedinfluenzavaccines
AT orbayasuko shapedependentadjuvanticityofnanoparticleconjugatedrnaadjuvantsforintranasalinactivatedinfluenzavaccines
AT mitomohideyuki shapedependentadjuvanticityofnanoparticleconjugatedrnaadjuvantsforintranasalinactivatedinfluenzavaccines
AT nakanotetsuo shapedependentadjuvanticityofnanoparticleconjugatedrnaadjuvantsforintranasalinactivatedinfluenzavaccines
AT hasegawahideki shapedependentadjuvanticityofnanoparticleconjugatedrnaadjuvantsforintranasalinactivatedinfluenzavaccines
AT ijirokuniharu shapedependentadjuvanticityofnanoparticleconjugatedrnaadjuvantsforintranasalinactivatedinfluenzavaccines
AT sawahirofumi shapedependentadjuvanticityofnanoparticleconjugatedrnaadjuvantsforintranasalinactivatedinfluenzavaccines
AT suzukitadaki shapedependentadjuvanticityofnanoparticleconjugatedrnaadjuvantsforintranasalinactivatedinfluenzavaccines
AT niikurakenichi shapedependentadjuvanticityofnanoparticleconjugatedrnaadjuvantsforintranasalinactivatedinfluenzavaccines